Positive Airway Pressure (PAP) devices are the first line treatment option recommended by the American Academy of Sleep Medicine (AASM) for OSA. Through the medium of a mask over the nasal, oral, or oronasal interface (nose, mouth or both), PAP devices create a pneumatic splint (air support) to open the upper airway that is prone to collapse during apneic events. PAP may be delivered in continuous (CPAP), bilevel (BiPAP), autotitrating (APAP) or adaptive servo ventilation (ASV) modes. PAP is the standard treatment recommended for moderate to severe OSA, and is a primary option for mild OSA.
Although PAP is the standard recommended clinical treatment modality for OSA (but not the only one), it requires proper introduction and education on the part of the Durable Medical Equipment (DME) provider, and an open mindset on the part of the patient. This is an extremely important dialogue, as PAP compliance statistics are generally poor, hovering at or just above 50%.
Evo Diagnostics highly recommends utilizing a reputable DME source for introduction to PAP. It is a well-known fact in the industry that compliance numbers can rise significantly with a proper introduction to a suitable interface. Nonetheless, the dialogue remains two-sided. If the patient's attitude has been skewed by irresponsible marketing of non-PAP commercial devices or social interactions that reflexively bias the individual against "sleeping with a mask", then PAP compliance will be an up-hill challenge. Based on the track record of PAP relative to some other forms of therapy for moderate to severe cases of OSA, we recommend that you give PAP a serious accommodation effort for the initial week after you have been prescribed the device if your physician has prescribed PAP. Once adapted, 76% of AASM survey respondents reported the quality of their sleep to be good to very good post treatment versus only 7% before (n=506). The same survey also disclosed that 41% of respondents were finally diagnosed with severe OSA and 43% were moderate even though the initial physician's assessment had 62% mild, 30% moderate and only 8% severe.